tfz Insider Perspectives July

In July, we’ll be discussing the question:
Switzerland as a Life Sciences Hub: Excellence or Decline?

What makes the culture of innovation in Switzerland’s pharmaceutical, medical, and biotech sectors unique—what threatens this competitive edge, and how can we maintain it? A preview of tfz Innovation Inside Pharma on September 3.

#Pharma-Cluster

Sara Käch | Senior Manager Government Affairs & Policy, Bristol Myers Squibb

"Switzerland’s innovative strength is based on a unique concentration of global corporations, biotech startups, cutting-edge research, and a reliable regulatory framework all within a very small area—resulting in the highest patent density in the world and attractive jobs. This competitive edge is under pressure: difficult market access, cost containment, and Switzerland’s new role as a U.S. reference country are jeopardizing future investments. For Switzerland to remain a leading location, it needs a clear pharmaceutical strategy and faster access for patients—health policy is also location policy.”

#Innovation

Martin Birk | CEO and Co-Founder, TransHeps

"The Swiss pharmaceutical sector thrives on the close connection between cutting-edge research and industry—at TransHeps, we’re a UZH spin-off and are currently preparing to collaborate with a major Swiss pharmaceutical company, while simultaneously undergoing review by the FDA. This connection doesn’t happen by chance; it’s actively nurtured. It is threatened by a lack of early-stage venture capital and regulatory processes that struggle to keep pace with scientific progress. To maintain this competitive edge, we need bolder early-stage investment and regulatory agencies that actively seek dialogue with innovative startups.”

#Patron #Framework

Dr. René P. Buholzer | CEO & Delegate of the Board, Interpharma

"Switzerland is one of the world’s leading life sciences hubs. This position is based on the synergy between excellent research, internationally networked companies, and highly qualified professionals. Due to tectonic shifts in the geopolitical landscape, international competition for talent, investment, and innovation is intensifying. To ensure that Switzerland remains an attractive location in the future and that new medical discoveries quickly benefit patients, targeted improvements to the framework conditions are necessary. These include attractive conditions for clinical research, responsible and practical access to health data, efficient and predictable procedures, timely access to innovations, and a clear life sciences strategy."